Global Blood Therapeutics stock has 11 Buy ratings from analysts. Price targets average to $55.73 which represents 71.73% upside from the previous closing price. Needham & Company, one of the most followed analyst firms because of their excellent record, set a price target on the stock today of $51 which is 57% upside from the previous close at $32.45.
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. You can read more about the company on their website.
Global Blood Therapeutics product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. In 2017, GBT440 is the most material catalyst unless GBT is acquired.
New data was release on October 11, 2017 that looks positive. You can read the GBT440 release here.
Global Blood Therapeutics Stock
GBT is currently showing a bull flag pattern. A bull flag pattern occurs when prices pull back slightly after a strong rise up. This may be a good opportunity for an entry. Large players volume looks beautiful and the Twiggs Money Flow is strong too. We see reduced volatility while prices have been consolidating. A pullback is taking place, which could present a good opportunity for an entry.
Global Blood Therapeutics Review
GBT has a Return On Assets of -31.60%. This is about inline with the industry average of -42.82%. The profitability ratios for GBT are negative, so there is not much use analyzing them. GBT has a weak Piotroski-F score of 3.
With a price book ratio of 4.95, GBT is fairly valued. GBT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative. Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GBT. No positive earnings are expected for the next year. When comparing the price book ratio of GBT to the average industry price book ratio of 3.93, GBT is more expensive than its industry peers.
The EPS growth is accelerating: in the next 2 years the growth will be better than in the last years. GBT is expected to show a decrease in Earnings Per Share. In the coming 2 years, the EPS will decrease by -7.19% yearly. GBT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -191.49%.
Health is where Global Blood Therapeutics shines. A Current Ratio of 13.70 indicates that GBT has no problem at all paying its short term obligations. GBT is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 4.65. GBT has better rating than 88% of its industry peers. GBT has a Quick Ratio of 13.70. This indicates that GBT is financially healthy and has no problem in meeting its short term obligations. GBT is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 4.48. GBT has better rating than 88% of its industry peers. GBT has an Altman-Z score of 40.93. This indicates that GBT is financially healthy and little risk of bankruptcy at the moment. GBT has one of the better Altman-Z scores in its industry. It is much better than the industry average of 1.70. GBT has a better score than 95% of its industry peers. The Piotroski-F score of GBT is 3 which is a low score.
Latest posts by Lance Jepsen
- YUM Brands Stock Retracement To Previous Resistance Setup - November 20, 2017
- Sarepta Therapeutics In Strong Uptrend From Exondys 51 - November 19, 2017
- Top 16 Companies With Earnings and Revenue Beats - November 19, 2017